Fig 1.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of studies identified from the systematic literature search [11].
Table 1.
Studies evaluating treatment patterns in patients with advanced non-small cell lung cancer by country.
Fig 2.
Second-line systemic regimen composition by country and time period.
Note: Percentages represent the proportions of patients who received the respective drug regimen out of all patients reported to receive second-line treatments.
a Per study investigators, 20% of patients’ second-line regimens were unreported.
Germany (2004–2006) and Canada (2005–2009): Patient population consisted of stage IV patients.
Europe (2003–2004): Countries included France, Germany, Portugal, Finland, Denmark, the United Kingdom, Sweden, the Netherlands, Israel, Romania, and Peru.
Europe (2006–2008): Countries included Finland, Germany, the Netherlands, Portugal, and the United Kingdom.
South Korea (2003–2008): All patients had platinum-based first-line therapy.
United States (2007–2011): Patient population consisted of metastatic non-squamous NSCLC.
United States (2001–2009): Patient population consisted of metastatic squamous NSCLC.
NSCLC, non-small cell lung cancer.
Table 2.
Summary of second-line treatment patterns.
Table 3.
Summary of survival outcomes by definition of survival time.
Table 4.
Summary of biomarker testing frequency and mutation prevalence by country.